Physician profile
Mark K Hafen
NPI 1306952056
$8,210.47
in general payments reported to CMS, 2019-2025
60 companies · $1,061 in 2025
The $1,061 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,046 · 2020: $822 · 2021: $1,468 · 2022: $1,354 · 2023: $1,469 · 2024: $991 · 2025: $1,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,237 · Education: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,236.83 |
| Education | $283.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,560.14 | 2020-2025 | |
| Astellas Pharma US INC | $1,251.84 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $701.26 | 2019-2025 | |
| Amgen INC. | $474.44 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $388.04 | 2019-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $355.23 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $311.48 | 2019-2024 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $225.81 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Supernus Pharmaceuticals, INC. | $182.62 | 2019-2025 | Qelbree, Qelbree |
| Abbott Laboratories | $181.66 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Tris Pharma INC | $177.60 | 2023-2025 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $150.17 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Sanofi-Aventis U.S. LLC | $118.71 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $111.69 | 2019-2025 | Spravato |
| Lundbeck LLC | $111.38 | 2025 | Vyepti, Rexulti |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hafen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.